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preparative regimen (IV busulfan); from day 0 to 100 patients
were admitted for a median of 11 days (0 – 25). We conclude
that in children, using ECP as part of RIC and GVHD preven-
tion is well tolerated and feasible, time to engraftment is ac-
ceptable, and complications are minimal as evidenced by short
inpatient stays. However, immune suppression appears to be
excessive given the rates of CMV reactivation and declining
chimerism of two patients while on ECP. ECP appears to be
effective in preventing aGVHD, as the only patients who de-
veloped aGVHD were those requiring immune modulation.
Table #1
Daignosis Donor
Chimerism
> 50%
(days)
Chimerism
> 95%
(days) aGVHD cGVHD
Disease
Status
1 CML Matched
Sibling
13 29 None None NED
following
DLI &
Imatinib
for
rising
BCR/ABL,
day
446
2 SAA Matched
Sibling
8 26 None Extensive NED,
day 390
3 CML Matched
Sibling
26 63
(Following
DLI)*
Grade 3 Extensive NED,
day 340
4 SAA Mismatched
Related
12 81
(Following
removal of
immune
supression)*
Grade 3 Limited NED,
day 284
5 Relapsed
ALL (CR2)
Matched
Sibling
12 28 None None Relapse,
day 100
6 Recurrent
HD (CR3)
MUD 20 33 None None Relapse,
day
100,
died of
PD
7 SAA Matched
Sibling
7 12 None None NED,
day 187
8 Recurrent
HD (CR2)
Matched
Sibling
28 47 None None NED,
day 124
9 SAA MUD No
engraftment
No
engraftment
None N/A Died
day
37,
fungal
infection
10 Peripheral
T-cell
Lymphoma
MUD 12 12 None N/A NED,
day 33
*Interventions due to falling chimerism
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COMBINED TACROLIMUS (FK-506) AND MYCOPHENOLATE MOFETIL
(MMF) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN
CHILDREN UNDERGOING CORD BLOOD TRANSPLANTATION (CBT)
Soni, S.1, Hente, M.2, Breslin, N.2, Bertolone, S.2, Cheerva, A.2 1Co-
lumbus Children’s Hospital, Columbus, OH; 2Kosair Children’s Hospi-
tal, Louisville, KY.
Background: Effectiveness of FK-506 and MMF combination as
prophylaxis for GVHD is still under investigation. We studied the
feasibility and effectiveness of this regimen in preventing GVHD
in children undergoing matched unrelated donor (MUD) CBT to
avoid methotrexate and methylprednisone toxicity.
Patients and Methods: Between 5/1/04-9/1/06, 11 children
undergoing MUD CBT have received FK-506 and MMF combi-
nation as prophylaxis for GVHD. Thymoglobulin (Rabbit ATG,
2.5-5mg/kg total) was used as part of the conditioning regimen.
Both myeloablative (n9) and non-myeloablative (n2) prepara-
tive regimens were used and majority of the children (n7) have
received one antigen mismatch (Class I/II-antigen disparate) CBT.
FK-506, 0.015mg/kg IV every 12 hours (infused over 6 hours) was
started on day-2 (trough level maintained 5-15 ng/ml),rather than
as a continuous infusion. MMF was started on day 1 at 15mg/kg
/dose IV q 8-12 hours and stopped on day 30, if there were no
signs of GVHD. Both were converted to PO formulation at the
time of discharge. MMF levels (active MPA) were monitored
weekly.
Results: The regimen was well tolerated. Only major side-effect
noted was hypertension in the ﬁrst 2 patients, which was controlled
with prophylactic anti-hypertensive use in subsequent patients.
Tremors occurred in 2 patients and responded to MMF taper. No
major neuro- or nephrotoxicity was noted. All children have en-
grafted (median16 days). No patient has developed Grade II
GVHD (Glucksberg staging criteria). 6/11 patients (54.5%) had
developed Grade I/II GVHD, limited only to skin and gut (1 pt.)
that was steroid-responsive. Only 1/6 patients continued to have
limited chronic GVHD of the skin (median follow-up: 255days ;
range: 62-725 days). Immune-reconstitution was not delayed.
MMF levels ranged from 0.5-5.7 mcg/ml. No correlation was
seen between the MMF levels and the incidence of GVHD in this
study.
Conclusion: FK-506/MMF combination is well tolerated, does
not affect engraftment kinetics or immune-reconstitution and is
efﬁcacious in preventing GVHD in CBT.
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HHV-6 INFECTION FOLLOWING CAMPATH1H BASED REDUCED INTEN-
SITY CONDITIONING (RIC) REGIMEN IN PEDIATRIC PATIENTS UNDER-
GOING SCT FOR NON-MALIGNANT DISORDERS
Soni, S.1, Barnes, Y.2, Hayashi, R.2, Manna, P.3, Shenoy, S.2 1Colum-
bus Children’s Hospital, Columbus, OH; 2Wahington University School
of Medicine, St. Louis, MO; 3Dept. of Molecular Diagnostic Research,
Viracor Laboratories, Lee’s Summit, MO.
Background: Human Herpes Virus 6 (HHV-6) infections have
been recently recognized as complications of SCT in young pa-
tients. Limited information is available on patterns and impact of
HHV-6 infection following RIC transplants using increased im-
munosuppression. We describe our multi-institutional experience
with HHV-6 infections during SCT following a Campath IH
based RIC regimen.
Patients and Methods: 12 patients underwent SCT for non-
malignant disorders and received Campath 1H (33mg/48mg, day
-21 and day-19); Fludarabine (150mg/m2,day -8 to -4) and Mel-
phalan (70 or 140mg/m2, day-3) prior to stem cell infusion (BM/
PBSC/CB) from related or unrelated donors. Two patients had
also received Thiotepa (10mg/kg on day-2). Acyclovir was used for
viral prophylaxis. Patients were tested for HHV-6 pre-transplan-
tation by a PCR based assay. Patients were monitored by HHV-6
PCR if they had fever, delayed engraftment/myelo-suppression,
rash or malaise. Serial quantitative real-time PCRs (viral load) data
was collected in some of these patients (Viracor Laboratories,
Missouri) to gauge response to treatment.
Results: All 12 patients undergoing SCT were negative for
HHV-6 by PCR pre-transplant. 7 patients (58.3%) had HHV-6
detected during the course of their SCT. Infections occurred
during the ﬁrst month (n4), second month (n1), at 4 months
(n1) and at 6months (n1) post-SCT. Common symptoms en-
countered were fever, rash and pancytopenia/delayed engraftment.
No case of pneumonitis or encephalitis was seen. HHV-6 infection
responded rapidly to Foscarnet or Gangcyclovir with decrease in
viral load and was associated with no deaths. No HHV-6 infections
were seen after immune-reconstitution (6 months).
Conclusions: Infection with HHV-6 infection is more frequent
following Campath based regimen. Most of the infections occur
within the ﬁrst 4 weeks and may delay engraftment; but late
infections are also common due to intense immunosuppression.
Therefore, close monitoring and early treatment is advocated in
pediatric patients receiving Campath 1H.
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UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANT FOLLOW-
ING INTRAUTERINE TRANSFUSIONS FOR TREATMENT OF ALPHA
THALASSEMIA MAJOR
Rivers, A.E.1, Richard, D.1, Harris, N.1, Chui, D.H.K.2,
Slayton, W.B.1, Staba, S.L.1 1University of Florida, Gainesville, FL;
2Hemoglobin Diagnostic Reference Laboratory, Boston, MA.
Homozygous 0-thalassemia (deletion of all 4 -globin genes)
results in Hb Bart’s (4 tetramers). Almost universally fetal death
from hydrops occurs prior to diagnosis, therefore not allowing the
opportunity for treatment. Advancement of maternal-fetal medi-
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